

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#215
NB
05/31/00

In re Application of: Coyler, et al.

U.S. Serial No.: 09/259,658

Filed: February 26, 1999

Entitled: Compositions And Methods For Monitoring The
Modification State Of A Pair Of Polypeptides



Group Art Unit: 1641

Examiner: V. Portner

Attorney Docket No.: 4256/79245

Assistant Commissioner for Patents

Box SEQUENCE

Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

In accordance with 37 C.F.R. § 1.825, please amend the above-referenced application, as follows.

In the specification:

At page 22, line 10, after
“HHHHHHGGIAQLEQEIAQLEQENAQLEQEIAQLEQEIAKLEQE”, insert --(SEQ ID NO:1)--;

At page 22, line 12, after “IAQLKQKIAQLKQKNAQLKQKIAQLKQKICQLKQK”,
insert --(SEQ ID NO:2)--;

At page 28, line 15, after “YXDED motif”, insert --(SEQ ID NO:3)--;

At page 30, line 12, after
“ILISLESEERGELERILADLEEENRNQLAEYDRLKQQHEHK”, insert --(SEQ ID NO:4)--;

At page 30, line 16, after “MKQLEDKVEELLSKNYHLENEVARLKKLVGER”,
insert --(SEQ ID NO:5)--;

At page 30, line 20, after
“TDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAH”, insert --(SEQ ID NO:6)--;

At page 30, line 24, after
"IARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNH", insert --(SEQ ID NO:7)--
;

At page 31, line 2, after
"VDKLGALERRKVLQVKTENLQAERNRSRKSIGQAKAR", insert --(SEQ ID NO:8)--;

At page 31, line 4, after "EPLRLEVNKLGEELDAAKAELDALQAEIRDIA", insert -
--(SEQ ID NO:9)--;

At page 31, line 10, after "DLEALLALDREVQELKKRLQEVQTERNQVAKRV",
insert --(SEQ ID NO:10)--;

At page 31, line 11, after "EALIARGKALGEEAKRLEEALREKEARLEALL", insert
--(SEQ ID NO:11)--;

At page 31, line 17, after "LRGAEKLREELDFLKSvFRPEIIAAIAEAR", insert --(SEQ
ID NO:12)--;

At page 31, line 19, after "AEYHAAREQQGFCEGRIKDIEAKLSN", insert --(SEQ ID
NO:13)--;

At page 31, line 25, after "MKQIEDKIEEILSKIYHIENEIARIKKLIGER", insert --
(SEQ ID NO:14)--;

At page 32, line 3, after "EWEALEKKLAALLESKLQALEKKLEALEHG", insert --
(SEQ ID NO:15)--;

At page 32, line 8, after "MKQIEDKLEEILSKLYHIENELARIKKLLGER", insert --
(SEQ ID NO:16)--;

At page 32, line 12, after "QEK TALNMARFIRSQTLTLLEKLNE", insert --(SEQ ID
NO:17)--;

At page 32, line 14, after "DEQADICESLHDHADELYRSCLAR", insert --(SEQ ID
NO:18)--;

At page 32, line 21, after "LILICLLLICHIVMLL", insert --(SEQ ID NO:19)--;

At page 37, line 14, below "Ltd." on line 13, insert the sentence --The sequence
identifiers for several of the protease cut sites listed above are as follows: Caspase 1,4,5,

B¹
cont.

W/LEHD-X (SEQ ID NO:20); Caspase 2,3,7 DEXD-X (SEQ ID NO:21); Caspase 6,8,9
L/VEXDX (SEQ ID NO:22); Factor Xa IEGR-X (SEQ ID NO:23); TEV E(N)XYXQ-S/G (SEQ
ID NO:24).--;

At page 69, line 15, after
“HHHHHHGGIAQLEQEIAQLEQENAYLEQEIAQLEQEIAKLEQE”, insert --(SEQ ID
NO:25)--;

At page 69, line 21, after “IAQLKQKIAQLKQKNAQLKQKIAQLKQKICQLKQK”,
insert --(SEQ ID NO:26)--;

At page 70, line 10, after
“HHHHHHGGIAQLEQEIAQLEQENRQLEQEIAQLEQEIAKLEQE”, insert --(SEQ ID
NO:27)--;

At page 70, line 16, after “IAQLKQKIAQLKQKNAQLKQKIAQLKQKICQLKQK”,
insert --(SEQ ID NO:28)--;

At page 71, line 5, after “EXXYXQS”, insert --(SEQ ID NO:29)--;

At page 71, line 11, after
“HHHHHHGGIAQLEQEIAQLEQENAYLQSEIAQLEQEIAKLEQE”, insert --(SEQ ID
NO:30)--;

At page 71, line 16, after “IAQLKQKIAQLKQKNAQLKQKIAQLKQKICQLKQK”,
insert --(SEQ ID NO:31)--;

At page 74, line 21, below “^{\$}Kemp”, insert the sentence --The sequence identifiers for
several of the protease cut/modification sites listed above are as follows: TEV E(N)XYXQ-S/G
(SEQ ID NO:24); Protein kinase A RRXRRXS (SEQ ID NO:32); CaM kinase II RXXSX (SEQ
ID NO:33); S6 kinase RXRXXS (SEQ ID NO:34).--;

B²

At page 75, line 4, after “R MKQLEDK VEELLSK TYHLENE VACLKKL
VGERAAK”, insert --(SEQ ID NO:35)--;

At page 77, line 28, after “R MKQLEDQ VRRLRRK SYHLENE VACLKKL
VGERAAK”, inset --(SEQ ID NO:36)--;

At page 78; line 3, after “R MKQLEDQ VRRLRRK TYHLENE VACLKKL

VGERRAAK", insert --(SEQ ID NO:37)--;

At page 80, line 18, after

"HHHHHHGGIAQLEQEIRRLRRESAQLEQEIAQLEQEIAKLEQE (Pep 1)", insert --(SEQ ID NO:38)--;

At page 81, line 5, after "(Pep 2)", insert --(SEQ ID NO:39)--;

At page 85, line 26, after "RXXSX", insert --(SEQ ID NO:33)--;

At page 86, line 3, after

"HHHHHHGGIAQLEQEIAQLRQESAQLEQEIAQLEQEIAKLEQE", insert --(SEQ ID NO:40)--;

At page 86, line 8, after "IAQLKQEIAQLKQKNAQLKQKIAQLKQKICQLKQK", insert --(SEQ ID NO:41)--;

At page 87, line 10, after "RXXSX", insert --(SEQ ID NO:34)--;

At page 87, line 15, after

"HHHHHHGGIAQLEQEIAQLRQESAQLEQEIAQLEQEIAKLEQE", insert --(SEQ ID NO:42)--;

At page 87, line 21, after "IAQLKQEIAQLKQKNAQLKQKIAQLKQKICQLKQK", insert --(SEQ ID NO:43)--;

At page 88, line 17, after "SAVSSADGTVL", insert --(SEQ ID NO:44)--;

At page 88, line 18, after

"HHHHHHGGIAQLEQEIAQLSAVSSALGTVLAQLEQEIAKLEQE", insert --(SEQ ID NO:45)--;

At page 89, line 2, after "IAQLKQKIAQLKQKNAQLKQKIAQLKQKICQLKQK", insert --(SEQ ID NO:46)--;

At page 89, line 28, after "Peptide I", insert --(SEQ ID NO:47)--;

At page 90, line 7, after "Peptide A", insert --(SEQ ID NO:48)--;

At page 93, line 15, after "Peptide C", insert --(SEQ ID NO:49)--;

At page 93, line 16, after "Peptide N", insert --(SEQ ID NO:50)--;

At page 93, line 18, after "*Peptide D*", insert --(SEQ ID NO:51)--;

At page 94, line 22, after "*Peptide 2*", insert --(SEQ ID NO:52)--;

At page 94, line 28, after "*Peptide 3*", insert --(SEQ ID NO:53)--;

At page 95, line 23, after "*Peptide 3*", insert --(SEQ ID NO:54)--;

At page 96, line 1, after "*peptide 33*", insert --(SEQ ID NO:55)--;

At page 97, line 5, after "*Peptide 4*", insert --(SEQ ID NO:56)--;

At page 97, line 11, after "*Peptide 44*", insert --(SEQ ID NO:57)--;

At page 99, line 1, after "*Peptide 5*", insert --(SEQ ID NO:58)--;

At page 99, line 4, after "*Peptide 5a*", insert --(SEQ ID NO:59)--.

In accordance with 37 C.F.R. § 1.821(e), enclosed is a 3.5 inch computer disk that contains a computer readable form of the paper "Sequence Listing." The disk is in IBM PC/AT format and contains the computer readable form of the paper "Sequence Listing" in ASCII text format, as the file name "sequence.lst". The computer readable form of the sequence listing is identical to the sequence listing submitted on paper, as required by 37 C.F.R. § 1.821(f), and contains no new matter. In accordance with the Office communication, enclosed is a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures. Applicants are directing this amendment to Examiner V. Portner.

Respectfully submitted,

Date

5/2/00

Kathleen A. Williams, Ph.D.

Reg. No. 34,380

Banner & Witcoff, Ltd.

28 State Street, 28th Floor

Boston, MA 02109

(617) 227-7111